Drug Trial Radar · NCT04517435
ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Feb 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
13
Actual
Start
Apr 28, 2021
Primary completion
May 17, 2023
Study completion May 17, 2023
Sponsor
- Lead sponsor
- Deepa JagadeeshAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Case Comprehensive Cancer Center
- First posted
- Aug 18, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to evaluate if ME-401 can improve the treatment of patients with diffuse large b-celllymphoma (DLBCL). Many patients with DLBCL that are treated with the standard of care (R-CHOP) are cured. However, a little less than half of patients will have their cancer come back despite being treated. Once DLBCL comes back, it is much harder to treat and treatment is much more aggressive. This study will combine ME-401 with R-CHOP. There are 2 parts to this study: part1 referred to as phase I and part 2 referred to as phase 2. The goal of the phase I study is to find the safest dose to give patients in combination with R-CHOP. The goal of the phase 2 study is to use the safest dose (found in phase 1) in combination with R-CHOP to see if it decreases the rate of cancer coming back after it is treated.
Conditions
- Diffuse Large B-Cell Lymphoma
Interventions
ME-401Drug
ME-401 (60 mg) will be given by mouth every 21 days for 6 cycles on days 1-4 (dose level 1) OR days 1-7 (dose level 2) of a 21 day cycle. Dose escalation will be performed in a standard 3+3 design
RituximabDrug
375 mg/m2 IV/subcutaneous rituximab day 1 of 21-day cycle. First dose of rituximab will be given IV and subsequent doses can be either IV or SQ based on institutional guidelines.
CyclophosphamideDrug
750 mg/m2 IV Cyclophosphamide day 1 of 21-day cycle
DoxorubicinDrug
50 mg/m2 IV Doxorubicin day 1 of 21-day cycle
VincristineDrug
1.4 mg/m2 (max 2 mg) IV Vincristine
PrednisoneDrug
100mg PO Prednisone Days 1-5 of 21-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I: Number of Clinically Significant Non-hematologic Grade 3 or 4 Treatment-related AEs or Hematologic Grade 3 or 4 Treatment Related AEsTime frame: Up to 24 months after treatment
- Phase II: Progression Free Survival (PFS) Assessed by Lugano CriteriaTime frame: 24 months (2 years)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
Cleveland, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.